Critical Limb Ischemia Global Market Report 2024

The critical limb ischemia market size has grown strongly in recent years. It will grow from $3.29 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth observed in the historical period can be attributed to an increase in cases of diabetes, tobacco consumption, the prevalence of hypertension, advancements in vascular imaging, the expansion of endovascular interventions, and progress in medical research and clinical trials.

The critical limb ischemia market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to advances in regenerative medicine, an emphasis on early intervention, the increasing prevalence of obesity, global health initiatives, and patient education programs. Noteworthy trends in the forecast period include the adoption of wearable health technologies, the expansion of telemedicine and remote patient monitoring, the integration of artificial intelligence (AI), the promotion of patient-centric care models, and the rise of minimally invasive interventions.

The anticipated surge in diabetes mellitus and peripheral artery diseases is poised to drive the expansion of the critical limb ischemia treatment market in the foreseeable future. Diabetes mellitus characterizes a metabolic disorder involving elevated blood glucose levels, while peripheral artery disease refers to the narrowing of leg arteries, leading to reduced blood flow to the limbs. These conditions significantly heighten the risk of vascular complications and amputation, thereby contributing to the occurrence of critical limb ischemia. The escalating prevalence of diabetes mellitus and peripheral artery diseases acts as a driving force behind the growth of the critical limb ischemia market. For example, as per data from the International Diabetes Federation in January 2022, the global prevalence of diabetes among 20-79-year-olds reached 536.6 million in 2021, expected to rise by 12.2% to 783.2 million by 2045. Furthermore, a journal published by Oxford University Press in March 2023 indicated that over 200 million individuals were affected by peripheral artery diseases in 2020, projected to surge by nearly 50% by 2045. Hence, the increasing incidence of these diseases fuels the critical limb ischemia treatment market.

The escalating investments in healthcare infrastructure are projected to propel the growth of the critical limb ischemia treatment market in the forthcoming years. Healthcare infrastructure investment encompasses the allocation of financial resources towards the development, enhancement, and maintenance of essential physical structures, facilities, and systems supporting healthcare service delivery. In the context of critical limb ischemia (CLI) treatment, healthcare infrastructure investments play a pivotal role by providing essential facilities, equipment, and resources for efficient diagnosis and treatment. For instance, according to the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services in March 2022, national health spending is anticipated to grow at an average annual rate of 5.1% between 2021 and 2030, reaching an approximate $6.8 trillion by 2030. Over the same period, Medicare and Medicaid expenditures are expected to increase by 7.2% and 5.6% annually, respectively. Consequently, heightened investments in healthcare infrastructure drive the critical limb ischemia treatment market's expansion.

Technological advancements stand out as a prominent trend gaining traction within the critical limb ischemia treatment market. Key enterprises operating in this domain are embracing new technologies to bolster their market standing. For instance, in January 2021, the Society for Vascular Surgery (SVS) in the United States launched three novel mobile applications catering to chronic limb-threatening ischemia treatment. These applications include the VQI CLTI Mortality Prediction Model, SVS Threatened Limb Classification [Wi-Fi] calculator, and Global Limb Anatomic Staging System [GLASS] calculator. Uniquely designed, these apps assist physicians in managing chronic limb-threatening conditions, enabling real-time estimation of patient risk, assessment of limb threat severity, and evaluation of disease complexity.

Key players in the critical limb ischemia market are strategically focusing on innovative solutions, such as a clinically engineered immobilization solution for the patient's leg, to establish a competitive edge in the market. These solutions delicately immobilize the patient's leg during fluoroscopy-guided treatments, providing crucial pressure management for individuals prone to painful ulcerations. For instance, in January 2022, Adept Medical, a New Zealand-based medical equipment manufacturer, introduced its Lower Leg Support product. This device is tailored to gently immobilize a patient's leg during fluoroscopy-guided critical limb ischemia treatments. Equipped to perform both endorotation and exorotation, the Lower Leg Support offers versatile positioning options while maintaining the foot in a slightly plantar-flexed posture for optimal imaging. Its ergonomic design aligns the leg to meet procedural requirements for lower limb interventions. The gadget features an adaptable footplate, enabling usage on either the left or right foot. Moreover, if foot manipulation is necessary during the procedure, the footplate can be entirely removed, allowing access for distal artery procedures, ultrasound imaging, and effective pressure management for patients experiencing frequent painful ulcerations. Additionally, the device includes soft foam straps to gently immobilize patients during conscious sedation.

In April 2021, Cardiovascular Systems Inc. (CSI), a prominent US-based medical device company, announced an undisclosed investment and acquisition option with CarePICS LLC. This partnership involved CSI's investment in CarePICS' data-driven solution and digital Software as a Service (SaaS) product, aimed at elevating patient outcomes. CarePICS, based in the United States, operates as a telehealth company offering a virtual care platform specifically designed to enhance outcomes for individuals affected by critical limb ischemia (CLI). The strategic investment by CSI in CarePICS demonstrates a commitment to leveraging advanced technology and data-driven solutions to improve patient care and treatment effectiveness within the critical limb ischemia domain.

Major companies operating in the critical limb ischemia market report are Medtronic Plc, Boston Scientific Corporation, ThermoGenesis Holdings Inc., Abbott Laboratories, Pluri Biotech Ltd., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Cynata Therapeutics Ltd, Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Aldagen Inc., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, Teleflex, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Soundbite Medical Solutions, Bluegrass Vascular Technologies, PQ Bypass, Vasorum Ltd, Rex Medical, Otsuka Medical Devices, Aortica Corporation.

North America was the largest region in the critical limb ischemia treatment market in 2023. The regions covered in the critical limb ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the critical limb ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of critical limb ischemia treatment include devices, drugs, and surgery. Embolic protection devices (EPDs) are medical devices designed to trap blood and luminal debris, preventing plaque debris from reaching the distal bed. Medications used in the treatment include antihypertensive agents, antiplatelet drugs, antithrombotic agents, and others. These treatments are administered in various healthcare settings, including hospitals, clinics, and other medical facilities.

The critical limb ischemia market research report is one of a series of new reports that provides critical limb ischemia market statistics, including critical limb ischemia industry global market size, regional shares, competitors with a critical limb ischemia market share, detailed critical limb ischemia market segments, market trends and opportunities, and any further data you may need to thrive in the critical limb ischemia industry. This critical limb ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.